Sibyl Anderson

2.7k total citations · 1 hit paper
40 papers, 2.1k citations indexed

About

Sibyl Anderson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Sibyl Anderson has authored 40 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 9 papers in Surgery. Recurrent topics in Sibyl Anderson's work include Sarcoma Diagnosis and Treatment (11 papers), Advanced Breast Cancer Therapies (6 papers) and Endometrial and Cervical Cancer Treatments (6 papers). Sibyl Anderson is often cited by papers focused on Sarcoma Diagnosis and Treatment (11 papers), Advanced Breast Cancer Therapies (6 papers) and Endometrial and Cervical Cancer Treatments (6 papers). Sibyl Anderson collaborates with scholars based in United States, Italy and France. Sibyl Anderson's co-authors include Ronald M. Bukowski, Bernard Escudier, Cezary Szczylik, Tim Eisen, Stéphane Oudard, Chetan Lathia, Michael Staehler, Carol Aghajanian, Thomas E. Hutson and Sylvie Négrier and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Sibyl Anderson

38 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Sibyl Anderson

Since Specialization

Citations

This map shows the geographic impact of Sibyl Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sibyl Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sibyl Anderson more than expected).

Fields of papers citing papers by Sibyl Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sibyl Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sibyl Anderson. The network helps show where Sibyl Anderson may publish in the future.

Co-authorship network of co-authors of Sibyl Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Sibyl Anderson. A scholar is included among the top collaborators of Sibyl Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sibyl Anderson. Sibyl Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and Evaluation of an Automated Multimodal Mobile Detection of Oral Cancer Imaging System to Aid in Risk-Based Management of Oral Mucosal Lesions 2025 ·Cancer Prevention Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Jennifer Carns, Richard A. Schwarz, (unknown), (unknown), Sibyl Anderson, Nancy Bass, Anthony B. Clayton, (unknown), (unknown), Rachel Giese, Ann M. Gillenwater, Nadarajah Vigneswaran, Rebecca Richards‐Kortum	4
2	Abstract PO1-19-12: VERITAC-2: a phase 3 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer 2024 ·Cancer Research ·Mario Campone, X. Cynthia, Michelino De Laurentiis, Hiroji Iwata, Sara A. Hurvitz, Seth A. Wander, Michael Danso, Dongrui R. Lu, Julia Perkins Smith, Yuan Liu, (unknown), Sibyl Anderson, Erika Hamilton	1
3	390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial 2023 ·Annals of Oncology ·Erika Hamilton, Hyo S. Han, Anne F. Schott, Antoinette R. Tan, Rita Nanda, Dejan Juric, (unknown), Pamela N. Münster, Bruno Fang, (unknown), (unknown), Richard Gedrich, Eric Zhi, (unknown), Weiwei Tan, (unknown), Jessica M. Perkins, Sibyl Anderson, Sara A. Hurvitz	12
4	VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. 2023 ·Journal of Clinical Oncology ·Mario Campone, X. Cynthia, Michelino De Laurentiis, Hiroji Iwata, Sara A. Hurvitz, Seth A. Wander, Michael Danso, Dongrui R. Lu, Julia Perkins Smith, Yuan Liu, (unknown), Sibyl Anderson, Erika Hamilton	30
5	Adherence Rates for Intravenous Chemotherapy Regimens to Treat Colon Cancer 2013 ·Value in Health ·Brian Seal, Carl V. Asche, (unknown), Sibyl Anderson, J. Cameron	1
6	Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET 2010 ·European Journal of Cancer ·Thomas E. Hutson, Joaquim Bellmunt, Camillo Porta, Cezary Szczylik, Michael Staehler, Andrea Nadel, Sibyl Anderson, Ronald M. Bukowski, Tim Eisen, Bernard Escudier	65
7	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial breakdown → 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, (unknown), Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski	864
8	Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET 2009 ·Medical Oncology ·Sylvie Négrier, Elke Jäger, Camillo Porta, David F. McDermott, Malcolm J. Moore, Joaquim Bellmunt, Sibyl Anderson, Frank Cihon, (unknown), Bernard Escudier, Ronald M. Bukowski	25
9	Combined modality chemoradiation in elderly oesophageal cancer patients 2007 ·British Journal of Cancer ·Sibyl Anderson, Bruce D. Minsky, Manjit S. Bains, Amanda Hummer, David P. Kelsen, David H. Ilson	61
10	Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important? 2006 ·International Journal of Gynecological Cancer ·Jakob Dupont, Carol Aghajanian, (unknown), Meghan Lovegren, Shaokun Chuai, E. S. Venkatraman, Martee L. Hensley, Sibyl Anderson, David R. Spriggs, Paul Sabbatini	6
11	p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas 2006 ·International Journal of Gynecological Cancer ·Sibyl Anderson, Daisuke Nonaka, Shaokun Chuai, Adam B. Olshen, D.S. Chi, Paul Sabbatini, Robert A. Soslow	29
12	Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy 2006 ·Cancer ·Shreyaskumar Patel, Mary Louise Keohan, Muhammad Wasif Saif, Daniel A. Rushing, Luis Báez, Kevie Feit, (unknown), Sibyl Anderson	37
13	Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study 2006 ·International Journal of Gynecological Cancer ·Mika A. Sovak, Jakob Dupont, Martee L. Hensley, Nicole Ishill, Scott R. Gerst, Nadeem R. Abu‐Rustum, Sibyl Anderson, R. Barakat, Jason Konner, Elizabeth Poyner, Paul Sabbatini, David R. Spriggs, Carol Aghajanian	43
14	Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma 2005 ·Gynecologic Oncology ·Aliza Leiser, Sibyl Anderson, Daisuke Nonaka, Shaokun Chuai, Adam B. Olshen, S. Dennis, Robert A. Soslow	44
15	Temozolomide in uterine leiomyosarcomas 2005 ·Gynecologic Oncology ·Sibyl Anderson, Carol Aghajanian	40
16	Paclitaxel and carboplatin (TP) for treatment of advanced or recurrent endometrial cancer: A retrospective study 2005 ·Journal of Clinical Oncology ·Mika A. Sovak, Shaokun Chuai, Sibyl Anderson, R. Barakat, Jakob Dupont, Martee L. Hensley, Paul Sabbatini, David R. Spriggs, Carol Aghajanian	3
17	Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma 2004 ·Cancer ·Mario M. Leitão, Robert A. Soslow, Daisuke Nonaka, Adam B. Olshen, Carol Aghajanian, Paul Sabbatini, Jakob Dupont, Martee L. Hensley, Yukio Sonoda, Richard R. Barakat, Sibyl Anderson	102
18	Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40 2004 ·Journal of Clinical Oncology ·Jakob Dupont, Meena K. Tanwar, Howard T. Thaler, Martin Fleisher, Noah D. Kauff, Martee L. Hensley, Paul Sabbatini, Sibyl Anderson, Carol Aghajanian, Eric C. Holland, David R. Spriggs	120
19	Phase II Trial of 96-Hour Paclitaxel in Previously Treated Patients with Advanced Esophageal Cancer 2003 ·Cancer Investigation ·Sibyl Anderson, Eileen M. O’Reilly, David P. Kelsen, David H. Ilson	16
20	Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel 2003 ·Gynecologic Oncology ·Don S. Dizon, Jakob Dupont, Sibyl Anderson, Paul Sabbatini, Amanda Hummer, Carol Aghajanian, D R Spriggs	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact